CYP3A4 and cancer: While the pregnancy model, implemented approximately a 100% increase in CYP3A4 expression and a 25% increase in renal function at 32 gestational weeks (Table 2), both simulation results showed that the pregnancy model overestimated paclitaxel exposure (around 40% higher) in pregnant patients with cancer (Table S12).